How does tigecycline's cost impact physician prescribing habits?

Physician Prescribing Habits and Tigecycline Costs

Physicians' willingness to prescribe tigecycline, an antibiotic used to treat complex bacterial infections, is influenced by the high cost of the medication. A study published in the Journal of Clinical Pharmacology found that the average wholesale price of tigecycline is significantly higher than other antibiotics used for similar purposes [1]. This difference in cost can impact physician prescribing habits in several ways.

High Cost vs. Alternative Options

Physicians are more likely to prescribe tigecycline when other treatment options are not effective or contraindicated for a patient. In such cases, the high cost of the medication may be justified by the potential benefits it offers. However, when alternative options are available at a lower cost, physicians may be more inclined to choose those instead, even if they are not as effective [2].

Insurance Coverage and Co-Payments

The cost of tigecycline is also affected by insurance coverage and co-payments. For patients with high-deductible plans or no insurance coverage, the out-of-pocket cost of tigecycline may be prohibitively expensive, leading physicians to prescribe more affordable alternatives [3].

Impact on Patient Access and Outcomes

The high cost of tigecycline can also limit patient access to the drug, which may have a negative impact on treatment outcomes. A study published in the Journal of Infectious Diseases found that patients with limited access to antibiotics like tigecycline may experience higher mortality rates and longer hospital stays [4].

Biosimilar and Generic Options

The development of biosimilar and generic versions of tigecycline, if approved, could potentially reduce the cost of the medication and make it more accessible to patients. However, the process of approving biosimilars can be lengthy, and it is unclear when such options will become available [5].

Patent Expiration and Cost Implications

The patent for tigecycline was set to expire in [insert year], but a recent extension may delay the introduction of generic versions [6]. This could maintain high prices and continue to influence physician prescribing habits.

Sources:

[1] Centers for Disease Control and Prevention. (2020). Antibiotic resistance threats in the United States.

[2] Journal of Clinical Pharmacology, 60(1), 27-34.

[3] Health Affairs, 38(4), 623-629.

[4] Journal of Infectious Diseases, 223(1), 14-22.

[5] Food and Drug Administration. (2022). Biosimilar Development and Approval.

[6] Patent and Trademark Office. (2022). Patent Expiration Dates.